Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The latest developments in endocrinology 2004/2005].

Christian Fottner1, Matthias M Weber

  • 1Schwerpunkt Endokrinologie und Stoffwechselerkrankungen, I. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universität, Mainz.

Medizinische Klinik (Munich, Germany : 1983)
|January 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.

European journal of heart failure·2025
Same author

Imaging-derived biomarkers from <sup>68</sup>Ga-DOTATOC PET/CT scans to predict survival of patients with neuroendocrine tumors after PRRT with <sup>177</sup>Lu-DOTATATE.

Cancer imaging : the official publication of the International Cancer Imaging Society·2025
Same author

Combined [<sup>18</sup>F]Fluorodeoxyglucose PET and [<sup>123</sup>I]Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias-the cross-sectional diagnostic test accuracy study FAMIAN.

EBioMedicine·2025
Same author

Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study.

Medicine·2025
Same author

Adult Growth Hormone Deficiency (AGHD) and Outcomes (NordiNet and ANSWER).

Journal of the Endocrine Society·2025
Same author

Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014
See all related articles

This review covers new treatments for osteoporosis, hyperparathyroidism, and male hypogonadism. It also discusses aldosterone

Area of Science:

  • Endocrinology
  • Pharmacology
  • Nuclear Medicine

Background:

  • Advances in endocrinology necessitate updates on diagnostic and therapeutic strategies.
  • Emerging treatments address conditions like osteoporosis, hyperparathyroidism, hypogonadism, and hypertension.
  • Novel imaging and therapeutic modalities are transforming endocrine tumor management.

Purpose of the Study:

  • To review recent advancements in endocrine diagnostics and therapeutics.
  • To highlight novel drug developments and their applications.
  • To discuss emerging imaging and radionuclide therapy techniques.

Main Methods:

  • Review of recent literature on pharmacological and diagnostic developments in endocrinology.
  • Discussion of new drug approvals and therapeutic applications, including strontium ranelate, teriparatide, cinacalcet, testosterone formulations, and eplerenone.

Related Experiment Videos

  • Presentation of novel diagnostic imaging ((18)F-DOPA-PET) and radionuclide therapy ((90)Y-DOTATOC) for endocrine tumors.

    • Main Results:

    • New treatments for postmenopausal osteoporosis (strontium ranelate, teriparatide) and male hypogonadism (testosterone undecanoate, gels) are available.
    • Cinacalcet offers therapeutic potential for hyperparathyroidism, and eplerenone for aldosterone-related conditions.
    • (18)F-DOPA-PET aids in localizing chromaffin tumors, and (90)Y-DOTATOC is effective for neuroendocrine tumors.

    Conclusions:

    • Significant progress has been made in endocrine therapeutics, offering new options for osteoporosis, hypogonadism, and hyperparathyroidism.
    • Emerging agents targeting the mineralocorticoid system and advanced imaging/therapy techniques are improving endocrine tumor management.
    • Ongoing research and clinical debate continue regarding subclinical hypothyroidism diagnosis and treatment.